Rain Therapeutics Inc.

General Information

We are a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile relative to available therapies, and we intend to continue strengthening our pipeline through focused business development and internal research efforts. Our lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which is oncogenic in numerous cancers. We in-licensed RAIN-32 in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors. This trial also validated a rationally-designed dosing schedule that has been shown to mitigate safety concerns and widen the therapeutic window of MDM2 inhibition, unlocking the potential for RAIN-32 in a broad range of MDM2-dependent cancers. Based on these data, we anticipate commencing a pivotal Phase 3 trial in LPS in the second half of 2021, a Phase 2 tumor-agnostic basket trial in certain solid tumors in the second half of 2021, and a Phase 2 trial in intimal sarcoma by early 2022. In addition to RAIN-32, we are also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.



Employees: 17
Founded: 2017
Contact Information
Address 8000 Jarvis Avenue, Suite 204 Newark, CA 94560
Phone Number (510) 953-5559
Web Address http://www.rainthera.com/
View Prospectus: Rain Therapeutics Inc.
Financial Information
Market Cap $441.49mil
Revenues $0 mil (last 12 months)
Net Income $-21.1 mil (last 12 months)
IPO Profile
Symbol RAIN
Exchange NASDAQ
Shares (millions): 7.4
Price range $17.00 - $17.00
Est. $ Volume $125.0 mil
Manager / Joint Managers Goldman Sachs/ Citigroup/ Piper Sandler/ Guggenheim Securities
CO-Managers -
Expected To Trade: 4/23/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change